Second‐line chemotherapy for locally advanced or metastatic small cell lung cancer
Referencias
Additional references
Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vaillancourt JM. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31:140‐9.
Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive‐stage disease small‐cell lung cancer. Journal of Clinical Oncology 2006;24:2038‐43.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration,2008. Available from www.cochrane‐handbook.org.
Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, et al. A multicenter randomized clinical trial comparing paclitaxel‐cisplatin‐etoposide versus cisplatin‐etoposide as first‐line treatment in patients with small‐cell lung cancer. Annals of Oncology 2001;12:463‐70.
NICE. Lung Cancer ‐ The diagnosis and treatment of lung cancer. NICE Clinical Guideline 242005:Section 1.8.
Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815‐34.
Pelayo Alvarez M, Gallego Rubio Ó, Bonfill Cosp X, Agra Varela Y. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database of Systematic Reviews 2009, Issue 4. [10.1002/14651858. CD001990]
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Schiller JH, Adak S, Cella D, DeVore RF, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive‐stage small‐cell lung cancer: E7593‐a phase III trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2001;19:2114‐22.
